PQA Pharmacy Performance Measures in Development


Pharmacy performance measures evaluate quality of pharmacies and assess pharmacist-provided care and pharmacy-based services. Pharmacy performance measures provide pharmacists the opportunity to demonstrate their contributions toward high-quality, patient-centered care.

PQA is developing a set of standard pharmacy performance measures that would be appropriate for pharmacy accountability, once assessed against standard measure criteria and endorsed by PQA membership.

Overview of Current Measure Development Work

PQA's Pharmacy Measure Development Action Plan guides the organization's continued work to build out a pharmacy measure set suitable for payer-pharmacy arrangements. It outlines next steps for developing measure concepts that were prioritized based on their feasibility and usability. PQA is launching three Technical Expert Panels (TEPs) to begin development of prioritized pharmacy measure concepts, including: 

  • Hemoglobin A1c Reporting and Blood Pressure Reporting (launching November 10, 2020)
  • Proportion of Days Covered (PDC) Composite: Renin Angiotensin System Antagonists, Statins, and Diabetes medications (November 18, 2020)
  • Antidepressant Medication Management (January 2021) 

PQA aims to complete development of these concepts to have the measures available for use in early 2022. Additional TEPs to develop prioritized concepts will be launched in the future.

Resources and Updates

Questions about PQA’s pharmacy measure development should be directed to PQA’s Performance Measurement Team at [email protected].

Learn More about the PQA Measure Development Process